Multivalent pneumococcal polysaccharide-protein conjugate composition

Patent metadata

Field	Value
Publication number	US-9399060-B2
Application number	US-201414322057-A
Country	US
Kind code	B2
Filing date	Jul 2, 2014
Priority date	Apr 8, 2005
Publication date	Jul 26, 2016
Grant date	Jul 26, 2016

Abstract

An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.

First claim

What is claimed is:

1. A multivalent immunogenic composition comprising polysaccharide-protein conjugates and a physiologically acceptable vehicle, wherein each of the conjugates comprises a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein, wherein the serotypes comprise 4, 6B, 9V, 14, 18C, 19F, 23F and at least one additional serotype, wherein the additional serotype is serotype 3, and wherein the carrier protein is CRM 197 .

2. The immunogenic composition of claim 1 , wherein the additional serotypes consist of serotypes 1, 3, 5, 6A, 7F and 19A.

3. The immunogenic composition of claim 1 , wherein said polysaccharide-protein conjugates consist of 13 distinct polysaccharide-protein conjugates, wherein each of the conjugates comprises a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein, and wherein the serotypes consist essentially of 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

4. The immunogenic composition of claim 1 , further comprising an adjuvant.

5. The immunogenic composition claim 4 , wherein the adjuvant is an aluminum-based adjuvant.

6. The immunogenic composition of claim 5 , wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.

7. The immunogenic composition of claim 6 , wherein the adjuvant is aluminum phosphate.

8. The immunogenic composition of claim 1 , wherein the composition further comprises one or more antigens.

9. The immunogenic composition according to claim 8 , wherein said one or more antigens is from a bacteria other than Streptococcus pneumoniae.

10. The immunogenic composition according to claim 9 , wherein said bacteria is selected from the group consisting of nontypable Haemophilus influenza, Moraxella catarrhalis and Alloiococcus otitidis.

11. The immunogenic composition of claim 1 , wherein the composition further comprises one or more proteins from Streptococcus pneumoniae.

12. The immunogenic composition of claim 1 , wherein the composition further comprises one or more proteins from Neisseria meningitidis type B.

13. The immunogenic composition of claim 1 , wherein the composition is formulated as a single 0.5 ml dose comprising 2.2 μg of each polysaccharide, except for 6B at 4.4 μg, and 125 μg aluminum phosphate adjuvant.

Assignees

• Wyeth Llc

Inventors

• Hausdorff William P
• Siber George Rainer
• Paradiso Peter R

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P27/16

  Otologicals · CPC title